Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lupin links with Polish firm to jumpstart Advair generic plans

This article was originally published in Scrip

Executive Summary

Lupin has unveiled plans for a significant step up in the inhalation therapy segment, with back-to-back announcements on its efforts for a generic version of GlaxoSmithKline's blockbuster asthma/COPD product, Advair/Seretide (salmeterol/fluticasone), and the launch in the US of a device to enhance delivery of aerosol therapies.

You may also be interested in...



Lupin’s US Advair Generic Plans Turn Awry As Celon Pact Nears End

Lupin’s plans for a US generic to GSK’s Advair Diskus have turned awry as its contract with Celon Pharma is close to being terminated. The company has focused on other respiratory drugs like generic ProAir and Fostair even as the revenue potential for Advair has been shrinking post Mylan’s launch.

Lupin’s US Advair Generic Plans Turn Awry As Celon Pact Nears End

Lupin’s plans for a US generic to GSK’s Advair Diskus have turned awry as its contract with Celon Pharma is close to being terminated. The company has focused on other respiratory drugs like generic ProAir and Fostair even as the revenue potential for Advair has been shrinking post Mylan’s launch.

Glenmark-Celon Generic Seretide DPI On Its Way In Europe

Glenmark-Celon’s generic Seretide Accuhaler dry powder inhaler (DPI) appears on course for a debut in Europe, piling up more pressure on GlaxoSmithKline’s respiratory franchise. Substitutability of the generic, however, will be key to driving momentum in uptake.

Topics

Related Companies

UsernamePublicRestriction

Register

SC027866

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel